Meritage Portfolio Management Has $366,000 Holdings in Danaher Co. (NYSE:DHR)

Meritage Portfolio Management trimmed its holdings in shares of Danaher Co. (NYSE:DHR) by 10.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,595 shares of the conglomerate’s stock after selling 194 shares during the quarter. Meritage Portfolio Management’s holdings in Danaher were worth $366,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Choreo LLC increased its position in Danaher by 4.4% during the fourth quarter. Choreo LLC now owns 21,703 shares of the conglomerate’s stock worth $4,984,000 after acquiring an additional 911 shares during the period. Tectonic Advisors LLC increased its position in Danaher by 7.6% during the fourth quarter. Tectonic Advisors LLC now owns 3,350 shares of the conglomerate’s stock worth $769,000 after acquiring an additional 238 shares during the period. Nvwm LLC increased its position in Danaher by 1.6% during the fourth quarter. Nvwm LLC now owns 5,592 shares of the conglomerate’s stock worth $1,284,000 after acquiring an additional 89 shares during the period. Confluence Wealth Services Inc. increased its position in Danaher by 4.3% during the fourth quarter. Confluence Wealth Services Inc. now owns 2,904 shares of the conglomerate’s stock worth $713,000 after acquiring an additional 120 shares during the period. Finally, Osprey Private Wealth LLC increased its position in Danaher by 1.1% during the fourth quarter. Osprey Private Wealth LLC now owns 11,250 shares of the conglomerate’s stock worth $2,582,000 after acquiring an additional 125 shares during the period. 79.05% of the stock is owned by institutional investors.

Danaher Stock Down 1.0 %

NYSE:DHR opened at $209.95 on Friday. The firm’s 50 day simple moving average is $233.96 and its 200 day simple moving average is $252.39. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. Danaher Co. has a one year low of $209.10 and a one year high of $281.70. The company has a market cap of $151.64 billion, a PE ratio of 39.76, a P/E/G ratio of 2.80 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the prior year, the firm posted $2.09 EPS. On average, research analysts anticipate that Danaher Co. will post 7.77 earnings per share for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Friday, December 27th were given a $0.27 dividend. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.51%. Danaher’s dividend payout ratio (DPR) is currently 20.45%.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on DHR shares. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Wells Fargo & Company decreased their target price on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. KeyCorp raised their target price on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Guggenheim started coverage on shares of Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price on the stock. Finally, TD Cowen raised their target price on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a report on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.